Susquehanna International Group
RPRX icon

Susquehanna International Group’s Royalty Pharma RPRX Stock Holding History

Susquehanna International Group’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$10.2M Buy
211,800
+102,600
+94% +$4.49M ﹤0.01% 3094
2025
Q4 		$4.22M Sell
109,200
-227,000
-68% -$8.66M ﹤0.01% 4296
2025
Q3 		$11.9M Sell
336,200
-111,100
-25% -$4.02M ﹤0.01% 2823
2025
Q2 		$16.1M Sell
447,300
-105,100
-19% -$3.48M ﹤0.01% 2254
2025
Q1 		$17.2M Buy
552,400
+368,000
+200% +$11.7M ﹤0.01% 1882
2024
Q4 		$4.7M Sell
184,400
-1,800
-1% -$47.7K ﹤0.01% 3688
2024
Q3 		$5.27M Buy
186,200
+43,100
+30% +$1.19M ﹤0.01% 3513
2024
Q2 		$3.77M Buy
143,100
+50,300
+54% +$1.39M ﹤0.01% 3902
2024
Q1 		$2.82M Sell
92,800
-64,800
-41% -$1.91M ﹤0.01% 4634
2023
Q4 		$4.43M Buy
157,600
+20,100
+15% +$552K ﹤0.01% 3914
2023
Q3 		$3.73M Sell
137,500
-54,000
-28% -$1.6M ﹤0.01% 4023
2023
Q2 		$5.89M Sell
191,500
-127,100
-40% -$4.3M ﹤0.01% 3263
2023
Q1 		$11.5M Sell
318,600
-49,300
-13% -$1.83M ﹤0.01% 2283
2022
Q4 		$14.5M Sell
367,900
-484,700
-57% -$20.2M ﹤0.01% 1824
2022
Q3 		$34.3M Buy
852,600
+97,700
+13% +$4.17M 0.01% 1030
2022
Q2 		$31.7M Buy
754,900
+435,300
+136% +$17.8M 0.01% 1116
2022
Q1 		$12.5M Buy
319,600
+85,100
+36% +$3.34M ﹤0.01% 2266
2021
Q4 		$9.35M Buy
234,500
+88,700
+61% +$3.45M ﹤0.01% 2815
2021
Q3 		$5.27M Sell
145,800
-144,900
-50% -$5.63M ﹤0.01% 3856
2021
Q2 		$11.9M Sell
290,700
-54,900
-16% -$2.34M ﹤0.01% 2668
2021
Q1 		$15.1M Buy
345,600
+229,400
+197% +$10.9M ﹤0.01% 2228
2020
Q4 		$5.82M Buy
116,200
+50,500
+77% +$2.14M ﹤0.01% 3199
2020
Q3 		$2.76M Buy
+65,700
New +$2.82M ﹤0.01% 4011

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Susquehanna International Group's RPRX Position: Q1 2026 in Review

Susquehanna International Group increased its Royalty Pharma (RPRX) stake by 154% in Q1 2026, buying an estimated $681K and bringing the position to 25,633 shares worth $1.23M. The position accounts for ﹤0.01% of the portfolio, ranked #7355.

Susquehanna International Group first reported a position in RPRX in Q2 2020 and has held it in 20 quarters since. The position peaked at $52.8M in Q4 2024. 587 funds tracked by Wall St. Rank hold RPRX as of Q1 2026.

  • Susquehanna International Group held 25,633 shares of Royalty Pharma worth $1.23M as of Q1 2026.
  • Susquehanna International Group bought 15,542 Royalty Pharma shares in Q1 2026, an estimated $681K.
  • Royalty Pharma made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #7355 holding.
  • Susquehanna International Group first reported a position in Royalty Pharma in Q2 2020 and has held it in 20 quarters since.
  • Susquehanna International Group's Royalty Pharma position peaked at $52.8M in Q4 2024.
  • 587 funds tracked by Wall St. Rank held Royalty Pharma as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.